Sharekhan's research report on Dr. Reddy’s Laboratories
Dr Reddy’s Laboratories has entered into an agreement for the development and commercialisation of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Dr. Reddy’s will make a USD 7.5 million upfront payment to Coya. Coya is also eligible to receive sales-based milestone payments of up to USD 677.25 million linked to tiers of cumulative net sales achieved over several years (over the term of the agreement subject to product commercial exclusivity). Under the Agreement, Dr. Reddy’s will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom for patients with ALS.
Outlook
Management retains its strong guidance of over 25% EBITDA margin in the near term, driven by settled product agreements like gRevlimid and double-digit growth in the India business. The stock trades at an attractive valuation of 17.3x and 15.4x its FY2025E and FY2026E estimates vs. peers’ 26x and 22.1x, indicating attractive valuations. Hence we maintain BUY with PT of Rs. 6,373.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.